Navigation Links
New results validating Pall prion reduction filter disclosed at ISBT Congress

Safety in transfusion medicine is an ongoing challenge to blood services worldwide as new threats, such as variant Creutzfeldt-Jakob Disease (vCJD), emerge. An update on the latest measures to protect the public from the human form of Bovine Spongiform Encephalopathy (BSE), commonly called Mad Cow Disease, and minimize risk of transmission through blood transfusion was presented here at the International Society of Blood Transfusion Congress. At the "Safety in Transfusion Medicine" symposium, Pall Corporation (NYSE: PLL) released new research results further validating the performance of its Leukotrap® Affinity Prion Reduction Filter System, which was CE marked with a 99.9 percent prion removal efficiency in May 2005. It is the first technology that reduces infectious prions from red cells, the most widely transfused blood component. Abnormal prions are believed to be the causative agent of vCJD.

The status of evaluations of the new filter system by blood authorities in Europe were also reported. Both the Irish Blood Transfusion Service (IBTS) and the English National Blood Service (NBS) are currently evaluating the filter system for integration into their respective practices to safeguard the blood supply from vCJD. Final results of these evaluations are expected by end 2005 or early 2006.

According to Dr. William Murphy, Medical Director of the IBTS, which just completed the first phase of its evaluation, "IBTS has completed laboratory evaluation of the filter; handling of the system is very straight forward and we are planning clinical studies in the coming months."

Dr. Roger Eglin, Head of the National Transfusion Microbiology Laboratory of the NBS, discussed the incidence and risk of vCJD transmission by blood transfusion. He reviewed the role of new technologies to reduce the risk of transfusion transmission of prions, noting that a potential impending approach is filtration.

He also discussed the status of blood donor testing to
'"/>

Source:Pall Corporation


Page: 1 2 3

Related biology news :

1. Gene vaccine for Alzheimers disease shows promising results
2. Roche clinical trial registry and results database launched
3. Diabetic nerve therapy shows striking results
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
6. Combination therapy shows promising results in patients with advanced lung cancer
7. Vaccine for brain tumors shows promising results
8. Artificial cornea offers better results for infants, some blind patients
9. Encouraging results in pancreatic cancer research
10. The eyes have it -- Autism research yields surprising results
11. UCSF brain tumor vaccine trial shows promising results
Post Your Comments:
(Date:8/22/2014)... and the bees. But that old expression leaves ... fertilization process for flowering plants is particularly complex ... female reproductive cells. New research from an international ... including Carnegie,s Wolf Frommer, David Ehrhardt, and Guido ... that guides flowering plant fertilization. It is published ...
(Date:8/21/2014)... unknown process for harvesting energy and producing oxygen from ... University scientist has discovered. The discovery lays the foundation ... energy from the Sun, and understanding dense blooms like ... worldwide. A paper describing the discovery will be published ... journal Science on 21 August 2014. , ...
(Date:8/21/2014)... Nine researchers from Beth Israel Deaconess Medical Center (BIDMC ... World,s Most Influential Scientific Minds 2014," a comprehensive ... a web resource for science metrics and research performance ... the most influential "are performing and publishing work that ... their science," according to a Thomson Reuters statement. Researchers ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... people experience X-ray computed tomography (CT) scanners when they are evaluated ... of Dr. Quin Liu, PhD., in Wuhan China, rice plants were ... of an agriculture study to increase rice yield. Into the ... in an automated facility that could process 4,320 rice plants a ...
... Inspired by Mother Nature, scientists are reporting development of ... to survive in a dormant condition for long periods despite ... in Journal of the American Chemical Society , they ... that protect anthrax and certain other bacterial cells, making those ...
... known that landfills produce methane, but had a hard time ... as a friendly environment for the organisms that produce methane. ... species of microbe is paving the way for other methane ... called Methanosarcina barkeri appears to be the key ...
Cached Biology News:Seeing rice with X-rays may improve crop yields 2Researchers ID microbe responsible for methane from landfills 2
(Date:8/21/2014)... 2014 DNA vaccine pioneer Immunomic ... development of JRC-LAMP-vax, an innovative and safe potential treatment ... studies began this month in Hawaii, moving the world ... The Japanese red cedar releases pollen that causes devastating ... Cedar pollen wreaks similar havoc in Colorado, New Mexico ...
(Date:8/21/2014)... Emmetsburg, IA (PRWEB) August 21, 2014 ... Project LIBERTY Opening , The Court of His Majesty ... King will attend the Grand Opening of POET-DSM Advanced ... on Wednesday, Sept. 3. , The King will take ... formal opening activity, scheduled for 11 a.m.-12:20 p.m. and ...
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
(Date:8/21/2014)... 21, 2014 Gallus BioPharmaceuticals ... development and manufacturing organization (CMO) announced today that ... an oncology company focused on the development of ... manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal ... Under the agreement the antibody will be ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... Jennerex, Inc., a private clinical-stage biotherapeutics company focused on ... products for cancer, today presented preliminary data from a ... with advanced liver cancer showing a benefit in overall ... from the study HEP007 indicated that the risk of ...
... 19, 2011 Metabolex, Inc., a biopharmaceutical company focused ... for the treatment of metabolic diseases, announced today that ... arhalofenate (MBX-102), its product candidate for the management of ... double-blind, placebo-controlled study will evaluate the safety and urate-lowering ...
... May 19, 2011 Reportlinker.com announces that ... in its catalogue: Global ... This report analyzes the ... The report provides separate comprehensive analytics for ...
Cached Biology Technology:Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 2Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 3Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 4Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 5Metabolex Initiates Phase 2 Trial of Arhalofenate 2Global Biosimilars Industry 2Global Biosimilars Industry 3Global Biosimilars Industry 4Global Biosimilars Industry 5Global Biosimilars Industry 6Global Biosimilars Industry 7Global Biosimilars Industry 8Global Biosimilars Industry 9Global Biosimilars Industry 10